BI
BioVie Inc.
BIVI · NASDAQ
$1.97 -5.52% (-$0.11)
1M +88.18%
Market Cap $15.3M
P/E Ratio -
Div. Yield -
ROE 126.02%
Bulios Fair Price
$1.07
45.7% downside
Current Price
$1.97
Undervalued Fair Value Overvalued
According to Bulios Fair Price, BIVI is currently overvalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Piotroski F-Score Weak
2/9Valuation
100 /100
Cheap P/B 1.49x
PEG N/A
P/S N/A
Growth
100 /100
Growing Book val. growth 8,648.15%
Rev. growth N/A
FCF growth N/A
Profitability
-
N/A Net margin N/A
Op. margin N/A
FCF margin N/A
Quality
0 /100
Poor ROE 126.02%
ROA 154.89%
Asset turnover 0.00x
Debt
69 /100
Low Current ratio 3.59x
Int. coverage -1,238.84x
Debt/Equity 0.03x
Stability
79 /100
Stable EPS volatility 15.80%
Profitable years 0
Beta 0.67x
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about BIVI
Online
Sector
Healthcare
Industry
Biotechnology
CEO
Cuong Viet Do
Employees
13
Headquarters
Carson City
Upcoming events
09 NOV
Earnings
Upcoming earnings report